You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: 102

    Project Summary Abstract Multiple Myeloma MM is the second most common form of blood cancer and remains an incurable and deadly disease Proteasome inhibitor PI therapy is a cornerstone in the treatment of MM but resistance to this class of agent is an emerging challenge in the clinic New therapeutic approaches that specifically target resistance are needed to maximize responses and ultimate ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. A novel protein engineering tool for rapid manufacturing of designer nucleosomes

    SBC: Epicypher, Inc.            Topic: 103

    PROJECT SUMMARY Nucleosomes are the basic building blocks of chromatin and composed of bp DNA wrapped around a core histone octamer Chromatin function is controlled by the dynamic addition removal of histone post translational modifications PTMs Significantly alterations in specific PTMs are associated with changes in gene expression driving the emergence progression of many cancer ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. The Effects of an Oral Nitric Oxide Lozenge on Peripheral Artery Disease

    SBC: Neogenis Laboratories, Inc.            Topic: 213

    Abstract Peripheral artery disease PAD is a common circulatory problem in which narrowed arteries reduce blood flow to your limbs thereby restricting blood flow During exercise or simply walking there is not sufficient blood flow to keep up with the metabolic demand This causes symptoms most notably leg pain when walking intermittent claudication PAD is also likely to be a sign of more w ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. A mobile app to reduce treatment-related financial burden for cancer patients

    SBC: Vivor, Llc            Topic: NCI

    There is a fundamental knowledge gap in how to immediately reduce cancer patientsandapos treatment related financial burden Cancer patients pay more out of pocket for their care than those with other chronic illnesses Half of all elderly cancer patients have high treatment related out of pocket financial burden This financial burden has well defined harmful effects even among insured cancer pa ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. An Ultra filtrate perfusion bio artificial pancreas for high-density islet replacement without immunosuppression

    SBC: Norfolk Medical Products, INC.            Topic: NIDDK

    DESCRIPTION provided by applicant The Cell SafeTM is a fundamentally new approach in replacement of dysfunctional insulin producing cells in patients with diabetes by transplantation of new islets in a three dimensional scaffold embedded in a highly compatible bioengineered perfusion system that continuously supplies tissue fluid blood ultrafiltrate so that the cells ae protected from immun ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Topical application of heterologous protein-expressing Staphylococcus epidermidis for potential therapeutic treatment of skin diseases

    SBC: Azitra Inc.            Topic: NIAID

    PROJECT SUMMARY Current treatment options for a number of skin diseases generally aim for symptomatic relief and fail to address underlying pathophysiological changes leading to skin disease In the case of genetic mutations that cause loss of function mutations supplementation of the missing protein is a viable approach to treatment However delivery of functional protein to the target keratino ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Polymeric Percutaneous Pulmonary Valve for Use in Young Children

    SBC: Polyvascular Corp            Topic: NHLBI

    DESCRIPTION provided by applicant Congenital heart defects CHD represent the most common type of birth defect and are a leading cause of childhood deaths in the developed world Many forms of CHD require pulmonary valve PV replacement surgery which is typically performed with biologic valves such as human cadaveric donor valves which are in short supply Additionally such biologically ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. A small molecule integrin activator to enhance cord blood transplant

    SBC: 7 Hills Pharma LLC            Topic: NHLBI

    DESCRIPTION provided by applicant This proposal is in response to PA the parent announcement for STTR R grant applications Hematopoietic stem cell transplantation has become a preferred treatment for hematological malignancies and certain genetic disorders The use of umbilical cord blood cells as a source of hematopoietic stem cells for bone marrow transplantation has increased st ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Proteolytic Imaging of Remodeling Myocardium

    SBC: Micro Vide, LLC            Topic: NHLBI

    DESCRIPTIONprovided by applicantProteolytic Imaging of Remodeling Myocardium Abstract Heart attacksi emyocardial infarction or MIoccur in more thanmillion patients annuallyAdvances in interventional and pharmacological therapies have dramatically improved survival following the initial MIand patients are often surviving acute MI with more extensive myocardial injuryConsequentlythe number of patien ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. A Bullet Proof vascular graft to prevent dialysis access cannulation injury

    SBC: Innavasc Medical, Inc.            Topic: 400

    Project Summary Abstract Synthetic arteriovenous grafts AVGs can provide life sustaining vascular access for dialysis patients but are subject to multiple modes of failure and complications related to chronic needle cannulation poor graft identification delayed access and bleeding These graft needle cannulation associated complications translate to millions of dollars in health care expense ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government